Jane Street’s Rubius Therapeutics, Inc RUBY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-23,784
Closed -$10K 10564
2022
Q3
$10K Sell
23,784
-42,345
-64% -$31.7K ﹤0.01% 9356
2022
Q2
$56K Buy
66,129
+28,364
+75% +$47.6K ﹤0.01% 8896
2022
Q1
$208K Buy
+37,765
New +$240K ﹤0.01% 8985
2021
Q2
Sell
-82,728
Closed -$2.07M 10675
2021
Q1
$2.19M Buy
82,728
+71,751
+654% +$1.05M ﹤0.01% 3839
2020
Q4
$83K Sell
10,977
-19,665
-64% -$117K ﹤0.01% 7247
2020
Q3
$154K Buy
+30,642
New +$162K ﹤0.01% 6586

Other funds holding RUBY

Jane Street's RUBY Position: Q4 2022 in Review

Jane Street sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 23,784 shares — an estimated $10K sold.

Jane Street first reported a position in RUBY in Q3 2020 and held it in 6 quarters. The position peaked at $2.19M in Q1 2021. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Jane Street reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Jane Street sold 23,784 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $10K.
  • Jane Street first reported a position in Rubius Therapeutics, Inc in Q3 2020 and held it in 6 quarters.
  • Jane Street's Rubius Therapeutics, Inc position peaked at $2.19M in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Jane Street's 13F filing for Q4 2022, filed 15 Feb 2023.